APA

Eggermont A. M. M., Chiarion-Sileni V. & Grob J. (20150813). Correction to Lancet Oncol 2015; 16: 522-30. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. : The Lancet. Oncology.

Chicago

Eggermont A M M, Chiarion-Sileni V and Grob J-J. 20150813. Correction to Lancet Oncol 2015; 16: 522-30. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. : The Lancet. Oncology.

Harvard

Eggermont A. M. M., Chiarion-Sileni V. and Grob J. (20150813). Correction to Lancet Oncol 2015; 16: 522-30. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. : The Lancet. Oncology.

MLA

Eggermont A M M, Chiarion-Sileni V and Grob J-J. Correction to Lancet Oncol 2015; 16: 522-30. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. : The Lancet. Oncology. 20150813.